6% Senior Convertible NOTEEndonovo Therapeutics, Inc. • July 15th, 2016 • Pharmaceutical preparations • New York
THIS 6% SENIORCONVERTIBLE NOTE is one of a series of duly authorized and validly issued 6% Senior Convertible Notes issued at a 5.5% original issue discount by Endonovo Therapeutics, Inc., a Delaware corporation (the “Company”) (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 15th, 2016 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July 8, 2016 by and between Endonovo Therapeutics, Inc., a Delaware corporation (the “Company”) and Bellridge LP (the “Purchaser). Capitalized terms used in this Agreement and not otherwise defined shall have the meanings ascribed to them in Article 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 15th, 2016 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT, is by and between Endonovo Therapeutics, Inc., a Delaware corporation (the “Company”), and Bellridge Capital LP(the “Holder”), and is made pursuant to that certain Securities Purchase Agreement between the Company and the Holder, dated as of the date hereof (the “Purchase Agreement”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 15th, 2016 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July 8, 2016, between Endonovo Therapeutics, Inc. a Delaware corporation (the “Company”), and Bellridge Capital, LP including its successors and assigns, a “Purchaser”).
